The pharmacology of agents that interfere with renin-angiotensin system activity

Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 4, 2006, Pages 247-250

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RENIN;

DRUG ANTAGONISM; DRUG EFFECT; HUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 84990386151     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.046     Document Type: Article

References (22)

1. Sica DA Newer antihypertensive agents: Angiotensin-receptor antagonists and aldosterone receptor antagonists. In: Atlas of Hypertension. Hollenberg N (Ed) (5th edition). Current Medicine, Inc. Philadelphia, PA. 2005:326-50.
2. Sica DA, Gehr TW, Ghosh S. Clinical pharmacokinetics of losartan. Clin Pharmacokinet 2005;44:797-814.
3. Gleiter CH, Morike KE Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002;41:7-17.
4. Mire DE, Silfani TN, Pugsley MK A review of the structural and functional features of olmesartan medoxomil, an angiotensin receptor blocker. J Cardiovasc Pharmacol 2005;46:585-93.
5. Sica DA Renal handling of angiotensin receptor blockers: clinical relevance. Curr Hypertens Rep 2003;5:337-9.
6. Sica DA Angiotensin receptor blockers - new considerations in their mechanism of action. J Clinical Hypertension 2006;8;381-5.
7. Maillard MP, Wurzner G., Nussberger J. et al. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing. Clin Pharmacol Ther 2002;71:68-76.
8. White WB, Lacourciere Y., Davidai G. Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure: impact on the early morning period. Am J Hypertens 2004; 17:347-53.
9. Weisser B., Gerwe M., Braun M., Funken C. [Investigations of the antihypertensive long-term action of candesartan cilexetil in different dosages under the influence of therapy-free intervals] Arzneimittelforschung 2005;55:505-13.
10. Sica DA, Gehr TWB, Frishman WH The renin-angiotensin axis: Angiotensin converting enzyme inhibitors and angiotensin-receptor blockers. In: Frishman W, Sonnenblick S, Sica DA (eds.) Cardiovascular Pharmacotherapeutics (2nd edition). New York, NY : McGraw-Hill. 2003: pp. 131-56.
11. Leblanc JM, Dasta JF, Pruchnicki MC, Schentag JJ Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors. J Clin Pharmacol 2006;46:968-80.
12. Dzau VJ, Bernstein K., Celermajer D. et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001;88 (suppl 9):1L-20L.
13. Rahuel J., Rasetti V., Maibaum J. et al. Structure-based drug design: the discovery of novel non peptide orally active inhibitors of human renin. Chem Biol 2000;7:493-504.
14. Nussberger J., Wuerzner G., Jensen C., Brunner HR Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 2003 ;39:E1-E8.
15. Azizi M., Webb R., Nussberger J., Hollenberg NK Renin inhibition with aliskiren: where are we now and where are we going? J Hypertens 2006;24:243-56.
16. Zhao C., Vaidyanathan S., Yeh CM et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006;45:1125-34.
17. Vaidyanathan S., Limoges D., Yeh C., Dieterich H. Aliskiren, an orally effective renin inhibitor, shows dose linear pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2006 ;79:64(PIII-23).
18. Vaidyanathan S., Jin Y., Schiller H., Jensen C. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Bas Clin Pharmacol Toxicol;97(suppl 1).
19. Gradman AH, Schmieder RE, Lins RL et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111: 1012-18.
20. Sica D., Gradman A., Lederballe I. et al. Aliskiren, an oral renin inhibitor, provides long-term antihypertensive efficacy and safety in patients with hypertension. Eur Heart J 2006;27(suppl):P797.
21. Feldman DL, Persohn E., Schutz H. et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens 2006;8 (suppl A):A80.
22. Herron J., Mitchell J., Oh B. et al. The novel renin inhibitor aliskiren is not associated with rebound effects on blood pressure or plasma renin activity following treatment withdrawal. J Clin Hypertens 2006;8(suppl A):A86.